Sotagliflozin and decompensated heart failure: results of the SOLOIST-WHF trial

Expert Rev Clin Pharmacol. 2021 May;14(5):523-525. doi: 10.1080/17512433.2021.1908123. Epub 2021 Apr 9.

Authors

Syed Raza Shah¹, Arroj Ali², Sohail Ikram³

Affiliations

¹ Cardiology Fellow, University of Louisville, Louisville, KY, USA.
² Department of Medicine, Lincoln Memorial University College of Osteopathic Medicine, Harrogate, TN, USA.
³ Department of Medicine, FACC-University of Louisville, Louisville, KY, USA.

PMID: 33764842
DOI: 10.1080/17512433.2021.1908123

No abstract available

Keywords: SOLOIST-WHF trial; Sotagliflozin; cardiovascular; heart failure.

Publication types

Editorial

MeSH terms

Glycosides / administration & dosage
Glycosides / pharmacology*
Heart Failure / drug therapy*
Heart Failure / physiopathology
Humans
Randomized Controlled Trials as Topic
Sodium-Glucose Transporter 2 Inhibitors / administration & dosage
Sodium-Glucose Transporter 2 Inhibitors / pharmacology

Substances

Glycosides
Sodium-Glucose Transporter 2 Inhibitors
(2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol